title: Vedolizumab  for Crohn's disease.
abstract: BACKGROUND
  Crohn's disease (CD) is a chronic inflammatory disorder of unknown aetiology. Currently, approved therapies that include prednisone, anti-metabolites and TNF antagonists, are often ineffective and frequently cause adverse effects. As a result, patients with CD can develop serious complications that adversely affect quality of life. Consequently, new treatment options are needed.
  
  
  METHODS
  This review discusses the potential role of vedolizumab, a humanised monoclonal antibody that selectively blocks lymphocyte trafficking to the gut, for the treatment of CD. All randomised placebo-controlled trials that evaluated vedolizumab for the treatment of CD were reviewed and safety and efficacy data evaluated.
  
  
  CONCLUSIONS
  Vedolizumab is an effective and well-tolerated drug that is an important advance for the treatment of CD.
authors: University of Western Ontario, Robarts Research Institute, Department of Medicine, Robarts Clinical Trials, 100 Perth Dr., London, ON N6A 5K8, Canada.
authors: Mahmoud H
authors: MH
authors: Mosli
authors: Brian G
authors: BG
authors: Feagan
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005765:Gastrointestinal Agents; C543529:vedolizumab